🟢 Recursion Pharmaceuticals Rises 4.6% on ARK Invest Buying and Russell Index Inclusion

Recursion Pharmaceuticals is trading at $3.89 (up 4.6%) today, buoyed by recent positive developments.

• ARK Invest significantly increased its holdings in RXRX on July 6, acquiring over 935,000 shares.
• The company was also added to several Russell value and small-cap benchmarks in late June, increasing its visibility to institutional investors.
• These positive catalysts are contributing to a rebound from earlier concerns related to a persistent pattern of insider net selling, including recent Form 144 filings by former CEO Christopher Gibson. The stock continues to face headwinds from high short interest.